Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(11%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_2
6
67%
Ph phase_1
1
11%
Ph not_applicable
1
11%
Ph phase_3
1
11%

Phase Distribution

1

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Other(2)

Detailed Status

Completed6
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 26 (66.7%)
Phase 31 (11.1%)
N/A1 (11.1%)

Trials by Status

unknown222%
recruiting111%
completed667%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_2

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT03686488
completedphase_2

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

NCT04417699
completedphase_2

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

NCT04923529
completedphase_3

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

NCT03520946
recruitingphase_2

TAS-102 and Anlotinib in ≥3 Lines mGC

NCT05029102
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03686488Phase 2

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Completed
NCT04417699Phase 2

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

Completed
NCT04923529Phase 2

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Completed
NCT03520946Phase 3

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed
NCT05029102Phase 2

TAS-102 and Anlotinib in ≥3 Lines mGC

Recruiting
NCT04517747Not Applicable

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

Completed
NCT03762161Phase 2

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Unknown
NCT03305913Phase 1

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Completed
NCT03909724Phase 2

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9